The puzzle of quality of life in schizophrenia: putting the pieces together with the FACE-SZ cohort.


Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
06 2022
Historique:
pubmed: 24 9 2020
medline: 28 6 2022
entrez: 23 9 2020
Statut: ppublish

Résumé

The determinants of quality of life (QoL) in schizophrenia are largely debated, mainly due to methodological discrepancies and divergence about the concepts concerned. As most studies have investigated bi- or tri-variate models, a multivariate model accounting for simultaneous potential mediations is necessary to have a comprehensive view of the determinants of QOL. We sought to estimate the associations between cognitive reserve, cognition, functioning, insight, depression, schizophrenic symptoms, and QoL in schizophrenia and their potential mediation relationships. We used structural equation modeling with mediation analyses to test a model based on existing literature in a sample of 776 patients with schizophrenia from the FondaMental Foundation FACE-SZ cohort. Our model showed a good fit to the data. We found better functioning to be positively associated with a better QoL, whereas better cognition, better insight, higher levels of depression, and schizophrenic symptoms were associated with a lower QoL in our sample. Cognitive reserve is not directly linked to QoL, but indirectly in a negative manner via cognition. We confirm the negative relationship between cognition and subjective QoL which was previously evidenced by other studies; moreover, this relationship seems to be robust as it survived in our multivariate model. It was not explained by insight as some suggested, thus the mechanism at stake remains to be explained. The pathways to subjective QoL in schizophrenia are complex and the determinants largely influence each other. Longitudinal studies are warranted to confirm these cross-sectional findings.

Sections du résumé

BACKGROUND
The determinants of quality of life (QoL) in schizophrenia are largely debated, mainly due to methodological discrepancies and divergence about the concepts concerned. As most studies have investigated bi- or tri-variate models, a multivariate model accounting for simultaneous potential mediations is necessary to have a comprehensive view of the determinants of QOL. We sought to estimate the associations between cognitive reserve, cognition, functioning, insight, depression, schizophrenic symptoms, and QoL in schizophrenia and their potential mediation relationships.
METHODS
We used structural equation modeling with mediation analyses to test a model based on existing literature in a sample of 776 patients with schizophrenia from the FondaMental Foundation FACE-SZ cohort.
RESULTS
Our model showed a good fit to the data. We found better functioning to be positively associated with a better QoL, whereas better cognition, better insight, higher levels of depression, and schizophrenic symptoms were associated with a lower QoL in our sample. Cognitive reserve is not directly linked to QoL, but indirectly in a negative manner via cognition. We confirm the negative relationship between cognition and subjective QoL which was previously evidenced by other studies; moreover, this relationship seems to be robust as it survived in our multivariate model. It was not explained by insight as some suggested, thus the mechanism at stake remains to be explained.
CONCLUSION
The pathways to subjective QoL in schizophrenia are complex and the determinants largely influence each other. Longitudinal studies are warranted to confirm these cross-sectional findings.

Identifiants

pubmed: 32962773
doi: 10.1017/S0033291720003311
pii: S0033291720003311
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1501-1508

Auteurs

Mickael Ehrminger (M)

University Paris Saclay - UVSQ, Health Sciences department, EA 4047 HANDIReSP, Laboratory for clinical and public health research on psychological, cognitive and motor disability, Versailles, France.
University Department of Adult Psychiatry and Addictology, Versailles Hospital, Le Chesnay, France.
University Paris Saclay, 'PsyDev' Team, CESP, Inserm, Villejuif, France.
Fondation Fondamental, Créteil, France.

Paul Roux (P)

University Paris Saclay - UVSQ, Health Sciences department, EA 4047 HANDIReSP, Laboratory for clinical and public health research on psychological, cognitive and motor disability, Versailles, France.
University Department of Adult Psychiatry and Addictology, Versailles Hospital, Le Chesnay, France.
University Paris Saclay, 'PsyDev' Team, CESP, Inserm, Villejuif, France.
Fondation Fondamental, Créteil, France.

Mathieu Urbach (M)

University Department of Adult Psychiatry and Addictology, Versailles Hospital, Le Chesnay, France.
Fondation Fondamental, Créteil, France.

Myrtille André (M)

Fondation Fondamental, Créteil, France.
University Department of Adult Psychiatry, La Colombière Hospital, Montpellier, France.

Bruno Aouizerate (B)

Fondation Fondamental, Créteil, France.
Department of Adult Psychiatry, Charles Perrens Hospital, Bordeaux, France.
University of Bordeaux, Laboratory of Nutrition and Integrative Neurobiology (UMR INRA 1286), France.

Fabrice Berna (F)

Fondation Fondamental, Créteil, France.
Department of Psychiatry, University Hospitals of Strasbourg, Strasbourg, France.
University of Strasbourg, INSERM U1114, Strasbourg, France.

Anne-Lise Bohec (AL)

Fondation Fondamental, Créteil, France.
University Claude Bernard Lyon 1, INSERM U1028, CNRS UMR5292, Lyon Center for Research in Neuroscience, PSYR2 Team, Le Vinatier Hospital, Bron, France.

Delphine Capdevielle (D)

Fondation Fondamental, Créteil, France.
University of Montpellier, PSNREC, Neuropsychiatry: Epidemiological and Clinical Research, INSERM, Montpellier, France.

Isabelle Chéreau (I)

Fondation Fondamental, Créteil, France.
Department of Psychiatry, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.

Julie Clauss (J)

Fondation Fondamental, Créteil, France.
Department of Psychiatry, University Hospitals of Strasbourg, Strasbourg, France.
University of Strasbourg, INSERM U1114, Strasbourg, France.

Caroline Dubertret (C)

Fondation Fondamental, Créteil, France.
Department of Psychiatry, Louis Mourier Hospital, Colombes, France.
University Paris Descartes, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France.
University Paris Diderot, School of Medicine, Sorbonne Paris Cité, Paris, France.

Julien Dubreucq (J)

Fondation Fondamental, Créteil, France.
Psychosocial Rehabilitation Reference Centre, Alpes-Isère Hospital, Grenoble, France.

Guillaume Fond (G)

Fondation Fondamental, Créteil, France.
Department of Public Health, La Conception University Hospital, Marseille, France.
School of medicine, University of Aix-Marseille, EA 3279, Marseille, France.

Roxana-Mihaela Honciuc (RM)

Fondation Fondamental, Créteil, France.
Department of Psychiatry, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.

Christophe Lançon (C)

Fondation Fondamental, Créteil, France.
School of medicine, University of Aix-Marseille, EA 3279, Marseille, France.
Department of Psychiatry, Sainte Marguerite University Hospital, Marseille, France.

Hakim Laouamri (H)

Fondation Fondamental, Créteil, France.

Sylvain Leigner (S)

Fondation Fondamental, Créteil, France.
Psychosocial Rehabilitation Reference Centre, Alpes-Isère Hospital, Grenoble, France.

Jasmina Mallet (J)

Fondation Fondamental, Créteil, France.
Department of Psychiatry, Louis Mourier Hospital, Colombes, France.
University Paris Descartes, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France.
University Paris Diderot, School of Medicine, Sorbonne Paris Cité, Paris, France.

David Misdrahi (D)

Fondation Fondamental, Créteil, France.
Department of Adult Psychiatry, Charles Perrens Hospital, Bordeaux, France.
University of Bordeaux, CNRS UMR 5287-INCIA, Bordeaux, France.

Baptiste Pignon (B)

Fondation Fondamental, Créteil, France.
INSERM U955, Translational Psychiatry Team, DHU Pe-PSY, Mondor University Hospital, Créteil, France.
School of medicine, University of Paris-Est, Créteil, France.

Romain Rey (R)

Fondation Fondamental, Créteil, France.
University Claude Bernard Lyon 1, INSERM U1028, CNRS UMR5292, Lyon Center for Research in Neuroscience, PSYR2 Team, Le Vinatier Hospital, Bron, France.

Franck Schürhoff (F)

Fondation Fondamental, Créteil, France.
INSERM U955, Translational Psychiatry Team, DHU Pe-PSY, Mondor University Hospital, Créteil, France.
School of medicine, University of Paris-Est, Créteil, France.

Christine Passerieux (C)

University Paris Saclay - UVSQ, Health Sciences department, EA 4047 HANDIReSP, Laboratory for clinical and public health research on psychological, cognitive and motor disability, Versailles, France.
University Department of Adult Psychiatry and Addictology, Versailles Hospital, Le Chesnay, France.
University Paris Saclay, 'PsyDev' Team, CESP, Inserm, Villejuif, France.
Fondation Fondamental, Créteil, France.

Eric Brunet-Gouet (E)

University Paris Saclay - UVSQ, Health Sciences department, EA 4047 HANDIReSP, Laboratory for clinical and public health research on psychological, cognitive and motor disability, Versailles, France.
University Department of Adult Psychiatry and Addictology, Versailles Hospital, Le Chesnay, France.
University Paris Saclay, 'PsyDev' Team, CESP, Inserm, Villejuif, France.
Fondation Fondamental, Créteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH